Coupon Accepted Successfully!


Recent Advances

Everolimus: an inhibitor of mTOR, approved for the treatment of patients with advanced kidney cancer
Belimumab:  A human monoclonal antibody that is specific for the cytokine B lymphocyte stimulator, have been approved by the US Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus.
Aprepitant: It is a selective, high-affinity antagonist at human NK1. When combined with a standard regimen of a corticosteroid (dexamethasone) and a serotonin 5-HT3 receptor antagonist (ondansetron), oral aprepitant (125mg on day 1 then 80mg once daily on days 2 and 3) was effective in the prevention of acute and delayed chemotherapyinduced nausea and vomiting (CINV) associated with single or multiple cycles of highly emetogenic chemotherapy (HEC).
Sunitinib: It is an oral multi-kinase inhibitor and works by blocking multiple molecular targets like vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), KIT, FLT3 and RET etc. It has now been approved for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. It is being used already for renal cell carcinoma.
Vandetanib: An orally available receptor tyrosine kinase (RTK) inhibitor, which blocks both the vascular endothelial growth factor (VEGF) and the Epidermal Growth Factor (EGF) receptor tyrosine kinase. Indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Ruxolitinib: It inhibits Janus associated kinases; JAK1 and JAK2. Approved for l treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis
Glucarpidase: It contains a recombinant enzyme, which rapidly lowers blood levels of methotrexate overdose.
Eculizumab: It is a monoclonal antibody that specifically binds to the complement protein C5. It is used for paroxysmal nocturnal hemoglobinuria.
Pazopanib: A multitargeted tyrosine kinase inhibitor against VEGF receptor -1,-2, and-3, PDGF receptor-α, β, and ckit indicated for the treatment of patients with advanced renal cell carcinoma.

Test Your Skills Now!
Take a Quiz now
Reviewer Name